Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure

Schmid, Irene; O'Neill, Allison F.; Watanabe, Kenichiro; Aerts, Isabelle; Branchereau, Sophie; Brock, Penelope R.; Dandapani, Madhumita; Fresneau, Brice; Geller, Jim; Hishiki, Tomoro; Ingham, Danielle; Kraal, Kathelijne; Ronghe, Milind; Tiao, Greg; Trobaugh-Lotrario, Angela; Rangaswami, Arun; Sullivan, Michael J.; Zsiros, Jozsef; Hiyama, Eiso; Malogolowkin, Marcio; Ansari, Marc

Abstract

Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (mainly European), COG (mainly North American) and JCCG (Japan), in concert, designed an international prospective clinical trial [PHITT (Paediatric Hepatic International Tumour Trial)/COGAHEP1531/JPLT4 - to be referred to as PHITT from this point forth] for the study of hepatoblastoma and hepatocellular carcinoma in children and adolescents. Recruitment to PHITT has recently concluded. The major results from this trial will be published in the next 2-3 years, therefore in the interim, we sought to provide a consensus statement on evidence-based chemotherapy guidance for hepatoblastoma and hepatocellular carcinoma of all stages.

Citation

Schmid, I., O'Neill, A. F., Watanabe, K., Aerts, I., Branchereau, S., Brock, P. R., Dandapani, M., Fresneau, B., Geller, J., Hishiki, T., Ingham, D., Kraal, K., Ronghe, M., Tiao, G., Trobaugh-Lotrario, A., Rangaswami, A., Sullivan, M. J., Zsiros, J., Hiyama, E., Malogolowkin, M., & Ansari, M. (2025). Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure. EJC Paediatric Oncology, 5, Article 100235. https://doi.org/10.1016/j.ejcped.2025.100235

• Journal Article Type: Article
• Acceptance Date: Apr 25, 2025
• Online Publication Date: May 7, 2025
• Publication Date: 2025-06
• Deposit Date: May 30, 2025
• Publicly Available Date: May 30, 2025
• Journal: EJC Paediatric Oncology
• Electronic ISSN: 2772-610X
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 5
• Article Number: 100235
• DOI: https://doi.org/10.1016/j.ejcped.2025.100235
• Keywords: Hepatoblastoma; Hepatocellular Carcinoma; Hepatocellular Neoplasm – Not Otherwise Specified; Interim guidance; Children; Chemotherapy
• Public URL: https://nottingham-repository.worktribe.com/output/49561819
• Publisher URL: https://www.ejcped.com/article/S2772-610X(25)00023-6/fulltext
• Additional Information: This article is maintained by: Elsevier; Article Title: Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure; Journal Title: EJC Paediatric Oncology; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ejcped.2025.100235; Content Type: article; Copyright: © 2025 The Authors. Published by Elsevier Ltd.